Brivaracetam

(Briviact®)

Brivaracetam

Drug updated on 4/26/2024

Dosage FormTablet (oral; 10 mg, 25 mg, 50 mg, 75 mg, 100 mg); solution (oral; 10 mg/mL); injection (intravenous; 50 mg/ 5 mL)
Drug ClassAnticonvulsants
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of partial-onset seizures in patients 1 month of age and older.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Brivaracetam (Briviact) is indicated for the treatment of partial-onset seizures in patients 1 month of age and older, demonstrating effectiveness in reducing seizure frequency when compared with placebo.
  • The information about brivaracetam was derived from a total of 12 systematic reviews/meta-analyses studies that provided extensive data on its efficacy and safety profiles.
  • Compared to other anti-seizure medications such as cenobamate, eslicarbazepine acetate, lacosamide, and perampanel; brivaracetam has shown a better tolerance profile despite having slightly lower efficacy in terms of ≥50% seizure frequency reduction.
  • In the pediatric population suffering from epilepsy, brivaracetam has demonstrated promising results both as monotherapy and adjunct therapy, with a notable retention rate of 78%, indicating its positive role in pediatric care.
  • For adults dealing with drug-resistant focal epilepsy, adding brivaracetam to their treatment may aid in reducing seizure frequency, but it is associated with a higher proportion of treatment withdrawals due to adverse events, which necessitates careful consideration.
  • Brivaracetam also showed effectiveness against refractory focal-onset seizures, suggesting potential utility for managing difficult-to-treat types while no increased risk of suicidality was observed among newer anti-seizure medications, including this one, contrasting FDA-mandated warnings attributed to older ones.
  • When used within the Korean context for treating focal epilepsy, third-generation AEDs, including brivaracetam, have shown better safety outcomes, implying a favorable risk-benefit profile across diverse populations.
  • While there are unique considerations required for elderly patients due to the complex clinical picture they often present, requiring a balance between efficacy and risk factors; more research is needed on the use of Anti-Epileptic Drugs like brivaracetam within this demographic group according to their specific needs and conditions.

Product Monograph / Prescribing Information

Document TitleYearSource
Briviact (brivaracetam) Prescribing Information.2023UCB, Inc., Smyrna, GA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
The efficacy and safety of third-generation antiseizure medications and non-invasive brain stimulation to treat refractory epilepsy: A systematic review and network meta-analysis study.2024Frontiers in Neurology
Safety and efficacy of brivaracetam in children epilepsy: A systematic review and meta-analysis.2023Frontiers in Neurology
Brivaracetam add-on therapy for drug-resistant epilepsy. 2022Cochrane Database of Systematic Reviews
Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: A systematic review and network meta-analysis2022Drugs
Anti-seizure medications and efficacy against focal to bilateral tonic-clonic seizures: A systematic review with relevance for SUDEP Prevention.2021Epilepsy & Behaviour
Brivaracetam: How well does it fare as an anti-epileptic? A review. 2021Neurology India
A meta-analysis: Efficacy and safety of anti-epileptic drugs prescribed in Korea as monotherapy and adjunctive treatment for patients with focal epilepsy. 2021Translational and Clinical Pharmacy
Suicidality Risk of Newer Antiseizure Medications: A Meta-analysis.2021JAMA Neurology
Therapeutic options for patients with refractory status epilepticus in palliative settings or with a limitation of life-sustaining therapies: A systematic review.2020CNS Drugs
Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis.2020Epilepsy and Behavior
Intravenous brivaracetam in the treatment of status epilepticus: A systematic review.2019CNS Drugs
The medical treatment of epilepsy in the elderly: A systematic review and meta-analysis.2019Epilepsia

Clinical Practice Guidelines

Document TitleYearSource
Epilepsies in children, young people and adults. 2022NICE
Clinical guidelines for the management of epilepsy.2020The Epilepsy Research Program of the Ontario Brain institute